Peptide preparation from bovine or porcine cerebral cortex; approved in Russia for CNS indications.
Low-molecular-weight peptide mixture proposed to exert neurotrophic and metabolic effects on cortical neurons.
Evidence summary in progress. See the citations section below for the underlying research papers.
No FDA label or editorial side-effect profile is on file for this compound yet. See the clinical trials and citations sections for study-reported safety data.
No documented drug interactions on file.
Not FDA approved. Approved in Russia; limited Western clinical-trial literature.
Not available via 503A/503B compounding pharmacies.
Regulatory data last verified 4/19/2026
No indexed ClinicalTrials.gov studies for Cortexin. This usually means the compound isn't being studied under an IND — check the citations section for peer-reviewed research instead.
Showing 20 of 30 papers. View all on PubMed →